Gamma Biosciences collaborates with Astrea Bioseparations for advanced application of Avacta Affimer Reagent Technology


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Gamma Biosciences collaborates with Astrea Bioseparations for advanced application of Avacta Affimer Reagent Technology
The agreement that gives Astrea the ability to secure exclusive access to the Affimer technology for applications in bioprocessing

Gamma Biosciences, a life sciences tools platform created by KKR, recently announced a licensing agreement between Astrea Bioseparations, a leader in affinity chromatography and bioseparations, and Avacta, a developer of innovative cancer therapies and diagnostics based on proprietary Affimer and preCISION platforms. The licensing agreement gives Astrea access to the Affimer technology for applications in bioprocessing, expanding its range of ligand discovery and development capabilities to include best-in-class chemical and biological platforms for customer development programs.

Affimer reagents are high-performance proteinaceous ligands that have been engineered for a wide range of applications as superior alternatives to antibody-based ligands. They can be used to selectively bind difficult targets, even where antibodies and aptamers have shown limitations. In combination with our proven Mimetic Ligand chemical ligand libraries, the Affimer ligand platform significantly expands our capacity to discover, develop and deliver custom affinity adsorbents for purification of biotherapeutics and advanced therapies,” said Dr Steve Burton, CEO of Astrea Bioseparations.

“Avacta chose to partner with Astrea based on its 35-year history of developing customized chromatography resins and affinity ligands, and a shared passion for advancing medicine. The license agreement includes an option that gives Astrea the ability to secure exclusive access to the Affimer technology for applications in bioprocessing. We look forward to partnering with the capable team at Astrea to enable new advances in the industry,” said Alastair Smith, CEO at Avacta.

“This agreement is a step forward as Astrea continues to redefine what is possible with affinity chromatography aligned with meticulous customer support. The license enables Astrea to provide an almost limitless repertoire of selective binding ligands with the ability to attach these to a variety of high-performance chromatography substrates, from PuraBead near-monodisperse agarose beads to the NanoPareilSM high-surface-area nano-fiber membranes,” said Phil Vanek, CTO at Gamma Biosciences.

Initial development work will focus on viral vectors and custom projects for third parties, leveraging the benefits of ligand diversity, stability, favorable elution conditions, and reproducible performance to address these traditionally challenging categories. The Astrea Bioseparations team expects to begin development of new products based on the technology early in 2021. Custom project inquiries are welcome and may be directed to Bruce Dawson at Astrea

Tags : #GammaBiosciences #LatestNewsonGammaBiosciences22ndDec #AstreaBioseparations #LatestNewsonAstreaBioseparations22ndDec #LatestPharmaNews22ndDec #LatestPharmaCollaboration22ndDec

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026